Editor's Choice | This Week in BMJ | Press releases

BMJ No 7122 Volume 315 Letters Saturday 13 December 1997 Use of statins See editorial by Muldoon p1554 Adequacy of SMAC's statement should be judged by clinicians, not health economists Peter Enoch Trent institute's research working group has produced guidance for purchasers R L Akehurst Other, cheaper and simpler, measures should be tried first Peter Sheridan and others In New Zealand, subsidy of statins is limited to particular groups of patients Win Bennett and others Guidelines need to concentrate on reducing overall cardiovascular risk A S Wierzbicki and T M Reynolds Faculty's advice does refer to cost effictiveness Alan Maryon Davis Results of different studies differed greatly D P Mikhailidis and A F Winder Glasgow has already produced strategy for treatment J McMurray and others Health authorities must work with clinicians to target statins Andrew P Wakeman and Robert H Leach More evidence is needed for guidelines David Lewis Evidence on effectiveness is stronger for statins than for other treatments E J Wallis and others Sheffield tables have shortcomings John Betteridge and others Cost effectiveness was studied in 4S study John Kjekshus and Terje R Pedersen Standing Medical Advisory Committee should reconsider advice to use Sheffield risk table Signed by 103 professors, consultants, and specialists in preventive cardiology, chemical pathology, metabolism and lipids, clinical pharmacology, epidemiology, and public health from England, Wales, and Northern Ireland Home | Current issue | Past issues | Classified ads | Career Focus | Feedback Collections | About this site | About the BMJ | BMA | Medline